rhGAD65 for New Onset Type 1 Diabetes

People get type 1 diabetes because their immune system, the part of the body which helps fight infections, mistakenly attack cells (beta cells) that produce insulin in your body.  As the immune system destroys these cells, the ability to produce insulin decreases and diabetes develops.

The goal of the study is to see if rhGAD65, by inducing immune "tolerance", will slow or prevent autoimmune destruction of the beta cells, thereby preserving  insulin production in new onset type 1 diabetes patients.  

If you would like more information on the “Effects of Recombinant Human Glutamic Acid Decarboxylase (rhGAD65) Formulated in Alum (GAD-alum) on the Progression of Type 1 Diabetes in New Onset Subjects” trial, please contact:

            Theresa Albright-Fischer, RN, BSN, CCRC
            Phone:  612-626-2182
            Toll free:  800-688-5252 Ext. 62182
            Email:  albr0088@umn.edu

            Or

            Jennifer Smith, BA
            Phone:  612-624-6682
            Toll free:  800-688-5252 Ext. 46682
            Email:  smit5759@umn.edu

You can download and print forms for the study by clicking on each document name.  Opening the file requires Adobe Reader. (Clicking on the link will open a new browser window.  To return to the website, please close down the new window.)

IRB approved consent (must be reviewed with staff at the University of Minnesota and signed for all being tested)

IRB approved HIPPA (for confidentiality of medical information)